Uro-oncology · KIMS Secunderabad
Renal Mass — What It Means When a Scan Finds a Solid Growth on the Kidney
A renal mass — a solid or complex growth within or on the kidney — is one of the most common incidental findings on abdominal ultrasound and CT scans. The prevalence of incidentally detected renal masses has increased dramatically over the past two decades as CT scanning has become more widely used in India for abdominal symptoms, health screening, and trauma evaluation. A solid renal mass — as opposed to a simple fluid-filled cyst — has a significantly higher probability of malignancy and requires a structured evaluation to determine its nature and the appropriate management.
Approximately 80 to 85% of solid enhancing renal masses are renal cell carcinoma (RCC) or one of its subtypes — malignant and requiring treatment. The remaining 15 to 20% are benign — most commonly angiomyolipoma (AML — a fat-containing benign tumour with characteristic CT appearance) or oncocytoma. The distinction between malignant and benign is made primarily on CT imaging characteristics — and the cornerstone of treatment for operable localised RCC is robotic partial nephrectomy (RAPN) or radical nephrectomy, performed at KIMS using the Da Vinci Xi or X.
How a renal mass is characterised
Solid mass with contrast enhancement (above 15 HU)
Likely diagnosis: Almost certainly malignant (RCC in 80–85%). Management: MDT review at KIMS tumour board · RAPN if below 7cm and technically feasible · Radical nephrectomy if above 7cm or complex anatomy · Biopsy in selected cases (metastatic disease, lymphoma, prior extra-renal malignancy).
Fat-containing mass (HU below −10 on non-contrast CT)
Likely diagnosis: Almost certainly angiomyolipoma (AML — benign). Management: Observe if below 4cm and asymptomatic · Embolisation or nephron-sparing surgery if above 4cm (bleeding risk) or symptomatic.
Homogeneous, uniform, low enhancement
Likely diagnosis: Oncocytoma (benign) vs chromophobe RCC (malignant) — radiologically indistinguishable. Management: Percutaneous renal biopsy or surgical resection. Oncocytoma cannot be reliably distinguished from chromophobe RCC on imaging alone.
Heterogeneous mass with necrosis, calcification
Likely diagnosis: Clear cell RCC (most common subtype — 70–75%). Management: RAPN or radical nephrectomy based on size and anatomy · Staging CT chest/abdomen/pelvis mandatory.
Cystic mass with solid enhancing components (Bosniak III or IV)
Likely diagnosis: Cystic RCC. Management: RAPN if feasible — see KIMS Renal Cyst page for Bosniak classification detail.
Staging — determining whether the cancer has spread
CT of the chest, abdomen, and pelvis with contrast
The standard staging investigation. Identifies lymph node involvement, adrenal involvement, venous tumour thrombus (extension of RCC into the renal vein or inferior vena cava — present in 4 to 10% of cases), and pulmonary or hepatic metastases.
Bone scan
For patients with bone pain or elevated alkaline phosphatase.
MRI
Superior to CT for assessing venous tumour thrombus extent (critical for surgical planning of IVC involvement).
Renal nuclear medicine (DTPA renogram)
Split renal function measurement is performed before partial or radical nephrectomy to establish the functional contribution of each kidney, particularly important when the contralateral kidney is at risk.
Treatment — nephron-sparing whenever possible
At KIMS, the approach to localised renal masses prioritises kidney-sparing surgery wherever technically and oncologically appropriate, with radical and ablative options reserved for defined indications.
Robotic partial nephrectomy (RAPN) — the preferred surgical approach for T1 tumours
For solid renal masses below 7cm (T1 stage), RAPN removes the tumour with a surgical margin while preserving the remaining kidney. This kidney-sparing approach maintains long-term kidney function — particularly important given that RCC patients often have the same risk factors (smoking, obesity, hypertension) that also cause CKD. Oncological outcomes for RAPN are equivalent to radical nephrectomy for T1a (below 4cm) tumours. At KIMS, RAPN is performed by Dr. Likhiteswer Pallagani using the Da Vinci Xi or X — 10x magnification and 7-degree articulation allow precise tumour excision and renorrhaphy (reconstruction of the kidney) even for complex tumours in difficult anatomical positions.
Robotic radical nephrectomy (RARN) — for large or complex tumours
For tumours above 7cm, tumours invading adjacent structures, or tumours with venous thrombus, radical nephrectomy — removal of the entire kidney — is the standard approach. Robotic radical nephrectomy provides a minimally invasive approach with faster recovery than open surgery.
Percutaneous ablation — for selected cases
Cryoablation or radiofrequency ablation of small renal masses (below 3cm) — for patients with bilateral tumours, solitary kidney, or those not fit for surgery. Performed by interventional radiology under CT guidance. Higher local recurrence rate than surgery; not the standard for fit patients.
Active surveillance — for very small masses in elderly or comorbid patients
Small solid renal masses (below 1.5 to 2cm) in elderly or frail patients may be safely observed with serial imaging — many grow slowly and the risk of metastasis is very low for small tumours. The growth rate and any change in imaging characteristics determine when intervention becomes appropriate.
The discovery of a solid renal mass on any scan requires urgent specialist evaluation — ideally within 2 to 3 weeks. Early-stage kidney cancer (T1a — below 4cm) has a 5-year cancer-specific survival above 95% with surgery. Delayed presentation reduces the chance of kidney-sparing surgery and increases the risk of metastatic disease. Call KIMS on 040-4488-5000 for an urgent uro-oncology appointment.
Book an Urgent Renal Mass Assessment at KIMS
Frequently Asked Questions — Renal Mass
A solid enhancing renal mass — one that shows increased density after IV contrast on CT — is RCC in approximately 80 to 85% of cases. This means 1 in 5 or 6 solid renal masses is benign (most commonly angiomyolipoma or oncocytoma). The CT characteristics — size, enhancement pattern, fat content, presence of necrosis or calcification — allow an experienced radiologist and urologist to assess the probability of malignancy. However, for most solid enhancing masses, surgical resection is recommended regardless — because the definitive diagnosis requires histopathology of the removed specimen, and the cure rate for early-stage RCC with surgery is excellent.
Partial nephrectomy removes only the tumour and a small margin of surrounding kidney tissue — preserving the rest of the kidney. It is preferred for tumours below 7cm (T1 stage) where technically feasible, because preserving kidney tissue maintains long-term kidney function and reduces the risk of CKD, cardiovascular disease, and dialysis in the years after surgery. Radical nephrectomy removes the entire kidney — indicated for larger tumours, tumours in complex positions, or tumours involving the renal hilum or vessels. Oncological outcomes are equivalent for T1 tumours — robotic partial nephrectomy at KIMS achieves the same cancer control as radical nephrectomy while preserving the kidney.
Percutaneous renal mass biopsy — a needle passed through the skin into the tumour under CT or ultrasound guidance — provides histological diagnosis without surgery. It is considered in specific situations: where the imaging characteristics suggest a non-surgical diagnosis (lymphoma, metastasis from another primary cancer, abscess), where the patient has known metastatic disease and the histological subtype is needed to guide systemic therapy, or where the patient is considering ablation (where histology before treatment is appropriate). For a fit patient with a solid enhancing mass who is planned for surgery, biopsy before nephrectomy is not routinely required — the surgical specimen provides the definitive diagnosis. At KIMS, the decision on pre-operative biopsy is made at the MDT tumour board.
Most localised solid renal masses do not require emergency surgery — but they should be assessed urgently (within 2 to 3 weeks) and treated within 4 to 8 weeks of diagnosis. Exceptions requiring more urgent management: a renal mass presenting with spontaneous retroperitoneal haemorrhage (usually from a bleeding AML — can be life-threatening, managed by emergency embolisation), or a very large mass with symptoms suggesting rapid growth or local invasion. For incidentally detected small masses (below 4cm) in elderly patients, a period of active surveillance to assess the growth rate is appropriate before committing to surgery.
KIMS Secunderabad — Dr. Likhiteswer Pallagani (Vattikuti Foundation uro-oncology fellowship, 400+ robotic cases, 3 peer-reviewed publications on robotic urology), MDT tumour board review of every renal mass, robotic partial nephrectomy (RAPN) with Da Vinci Xi AND X, robotic radical nephrectomy, DTPA renogram for split function, CT staging. NABH and NABL accredited. Call 040-4488-5000.